Evaluating the Clinical Impact of CYP2C19 and CYP2D6 on Amitriptyline Outcomes in a Real-World Chronic Pain Cohort
Bade Uckac, Santiago Díaz‐Torres, Zuriel Ceja, Natalia S. Ogonowski, Penelope A. Lind, Dale R. Nyholt, Nicholas G. Martin, Sarah Elizabeth Medland, Miguel E. Rentería, Giovanni Esteves Ferreira
This study examines the association between CYP2C19 and CYP2D6 metabolizer phenotypes and amitriptyline effectiveness and tolerability in a chronic pain cohort, finding no strong associations after correction for multiple testing.
medRxiv · Jun 5, 2026 · PreprintGenetic & Genomic Medicine